Valuation: Ono Pharmaceutical Co., Ltd.

Market Cap 1,103B 6.79B 5.93B 5.49B 5.03B 9.53B 654B 9.69B 65.43B 25.7B 319B 25.49B 24.93B P/E 2027 *
15.5x
P/E 2028 * 17.6x
Enterprise Value 903B 5.56B 4.86B 4.5B 4.13B 7.81B 536B 7.94B 53.61B 21.06B 262B 20.88B 20.43B EV / Sales 2027 *
1.99x
EV / Sales 2028 * 1.99x
Free-Float
80.98%
Yield 2027 *
3.34%
Yield 2028 * 3.3%
06-19 Mizuho Securities Upgrades Ono Pharmaceutical to Buy from Neutral; Price Target is 3,200 Yen MT
06-18 Ono Pharmaceutical to Dispose of 47 Million Yen Treasury Shares Under Stock Compensation Plan MT
06-01 Ono Pharmaceutical Co., Ltd. Announces Oral Presentation Of New Data From The Phase 2 Clinical Study Of ONO-4578 In Certain Gastric Cancers At The ASCO 2026 Annual Meeting CI
05-29 Jefferies Adjusts Ono Pharmaceutical's Price Target to 2,500 Yen From 1,750 Yen, Keeps at Hold MT
05-08 Ono Pharmaceutical's Attributable Profit Jumps 39% in Fiscal Year 2025 MT
05-07 Ono Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-07 Ono Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-07 Ono Pharmaceutical Co., Ltd. Proposes Year End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 19, 2026 and Provides Dividend Forecasts for the Second Quarter of Year Ending March 31, 2027 and Fiscal Year Ending March 31, 2027 CI
04-22 Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say RE
1 day+3.58%
1 week-0.76%
Current month+1.78%
1 month+7.59%
3 months-2.47%
6 months+7.52%
Current year+11.88%
1 week 2,344.5
Extreme 2344.5
2,471.5
1 month 2,208
Extreme 2208
2,507
Current year 2,114.5
Extreme 2114.5
2,674.5
1 year 1,579.5
Extreme 1579.5
2,674.5
3 years 1,474
Extreme 1474
2,966.5
5 years 1,474
Extreme 1474
3,990
10 years 1,474
Extreme 1474
4,107
Manager TitleAgeSince
Chief Executive Officer 67 2024-03-31
Director of Finance/CFO - 2026-03-31
President 57 2024-03-31
Director TitleAgeSince
Chairman 67 2024-03-31
Director/Board Member 57 2020-05-31
Director/Board Member 76 2018-06-25
Change 5-day change 1-year change 3-year change Capi.($)
+3.60%-0.76%+46.42%-3.55% 6.92B
-0.07%+3.28%+12.89%+81.75% 48.66B
+1.32%+0.99%+69.73%+115.50% 35.52B
-0.59%-0.16%-4.12%+38.67% 12.07B
-0.26%+0.51%+19.25%+93.82% 11.99B
0.00%+2.29%+34.34%+129.06% 9.29B
+0.50%+0.50%+19.50%+37.94% 7B
-0.46%+2.84%+2.73%+225.72% 6.74B
+7.04%+14.92%-10.65%+29.12% 6.36B
-0.04%+5.31%+27.99%+139.09% 4.48B
Average +1.11%+2.15%+21.81%+88.71% 14.9B
Weighted average by Cap. +0.71%+1.54%+27.76%+90.19%

Financials

2027 *2028 *
Net sales 454B 2.8B 2.44B 2.26B 2.07B 3.93B 269B 3.99B 26.96B 10.59B 132B 10.5B 10.27B 444B 2.74B 2.39B 2.21B 2.03B 3.84B 264B 3.91B 26.38B 10.36B 129B 10.27B 10.05B
Net income 70.97B 437M 382M 353M 324M 613M 42.1B 624M 4.21B 1.65B 20.56B 1.64B 1.6B 62.51B 385M 336M 311M 285M 540M 37.08B 550M 3.71B 1.46B 18.11B 1.45B 1.41B
Net Debt -199B -1.23B -1.07B -991M -910M -1.72B -118B -1.75B -11.82B -4.64B -57.7B -4.6B -4.5B -218B -1.34B -1.17B -1.09B -996M -1.89B -129B -1.92B -12.95B -5.09B -63.21B -5.04B -4.93B
Logo Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company is engaged in the manufacture and sale of prescription and over-the-counter drugs. The Company has been particularly focused on research and development of prescription drugs, positioning them as its core business. The Company’s products include injectables, oral medications, and patches.
Employees
4,206
Date Price Change Volume
26-07-16 JP¥2,431.00 +3.60% 274,800
26-07-16 JP¥2,346.50 -1.76% 1,579,900
26-07-15 JP¥2,388.50 -1.81% 1,516,100
26-07-14 JP¥2,432.50 +1.33% 1,327,200
26-07-13 JP¥2,400.50 -1.13% 1,072,800
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
2,346.50JPY
Average target price
2,500.00JPY
Spread / Average Target
+6.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4528 Stock